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Abstract
Objective: There is a lack of standardisation in the terminology used to describe gout. The aim 
of this project was to develop a consensus statement describing the recommended nomenclature 
for disease states of gout.
Methods: A content analysis of gout-related articles from rheumatology and general internal 
medicine journals published over a five year period identified potential disease states and the 
labels commonly assigned to them. Based on these findings, experts in gout were invited to 
participate in a Delphi exercise and face-to-face consensus meeting to reach agreement on disease 
state labels and definitions.
Results: The content analysis identified 13 unique disease states and a total of 63 unique labels. 
The Delphi exercise (n=76 respondents) and face-to-face meeting (n=35 attendees) established 
consensus agreement for eight disease state labels and definitions. The agreed labels were: 
‘asymptomatic hyperuricemia’, ‘asymptomatic monosodium urate crystal deposition’, 
‘asymptomatic hyperuricemia with monosodium urate crystal deposition’, ‘gout’, ‘tophaceous 
gout’, ‘erosive gout’, ‘first gout flare’ and ‘recurrent gout flares’. There was consensus agreement 
that the label ‘gout’ should be restricted to current or prior clinically evident disease caused by 
monosodium urate crystal deposition.
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Conclusion: Consensus agreement has been established for the labels and definitions of eight 
gout disease states, including ‘gout’ itself. The Gout, Hyperuricemia and Crystal-Associated 
Disease Network (G-CAN) recommends the use of these labels when describing disease states of 
gout in research and clinical practice.
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INTRODUCTION
The language used to describe gout is characterised by a lack of consistent terminology and 
definitions.1,2 In particular, many different terms are used interchangeably to describe 
different disease states and their constituent features. This lack of agreement and clarity has 
implications for how disease related concepts are communicated in both clinical and 
research settings.3–5 Notably, there is no universally accepted definition of ‘gout’ itself.6
The Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) is an 
international, multidisciplinary network for collaborative research, committed to advancing 
all aspects of the crystal deposition-associated disorders. G-CAN has supported a project to 
establish consensus agreement on the nomenclature of hyperuricaemia and gout, its primary 
objective being the promotion of accurate, well defined, terms that facilitate understanding 
of disease related concepts. The intended audience is health care professionals and non-
physician scientists in clinical and research settings.
In the first stage of the G-CAN gout nomenclature project, consensus agreement was 
reached on the labels and definitions of the disease elements of gout. The content analysis of 
the literature and subsequent G-CAN-endorsed consensus statement have been published, 
with the results of the latter summarised in Table 1.1,7 Using these results as a framework, 
the objective of this second stage of the G-CAN gout nomenclature project was to reach 
agreement on the nomenclature of disease states of gout. For the purpose of this project, a 
disease state was defined as ‘a clinically meaningful cluster of the presence, or absence, of 
two or more disease elements’. Here, we describe the process and outcomes of this project 
addressing the labels and definitions of the disease states of gout.
METHODS
This work consisted of three components: a content analysis of the literature, a Delphi 
exercise and a face-to-face consensus meeting. The content analysis of the literature was 
performed to identify the language currently used to represent disease states of gout. The 
results of this analysis were then used as the basis for two group consensus exercises - a 
Delphi exercise and a face-to-face meeting - with the overall objective of reaching 
agreement on a nomenclature for disease states of gout. A schematic representation of these 
project components is shown in Figure 1.
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Content analysis of the literature
This component of the project had two aims: first, to establish the range of disease states 
described in the contemporary gout- and hyperuricemia-related literature; and second, to 
identify the labels currently used to denote these disease states. Articles were extracted from 
the ten highest-ranked general rheumatology journals, and the five highest-ranked general 
internal medicine journals (according to Impact Factor, 2016 Thomson-Reuters Journal 
Citation Reports) published between 1st January 2013 and 31st January 2018. These journals 
are shown in Supplementary Table S1. Relevant articles within each journal were identified 
through MEDLINE using the search terms ‘gout’ or ‘urate’ or ‘hyperuricemia’ without 
exclusion criteria. This methodology was used to provide a suitably large representation of 
contemporary literature for the extraction of disease states and their labels, with the intention 
of reflecting the current language of gout and hyperuricaemia, rather than its progression 
over time.
For the purpose of this project, a disease state was defined as a ‘clinically meaningful cluster 
of the presence, or absence, of two or more disease elements’. The G-CAN-endorsed labels 
and definitions for the disease elements of gout are summarised in Table 1. A cluster was 
considered ‘meaningful’ if the co-occurrence of these disease elements had the potential to 
impact either disease prognosis or management. Articles were manually searched for 
passages of text referring to the collective presence, or absence, of two or more disease 
elements. Labels for each identified disease state were extracted to determine the range and 
frequency of unique labels. Disease state labels were taken verbatim from the examined text, 
except where the labels for component disease elements were modified to comply with 
existing G-CAN consensus statement for disease elements (as shown in Table 1). Labels 
were considered ‘unique’ if they used different words or phrases to describe a disease state. 
For each article, the use of a unique label was recorded only once. All articles were analyzed 
by a single investigator (DB). To ensure the accuracy of the disease state and label 
identification, the first 10 articles examined were jointly reviewed by a second investigator 
(ND) with 98% agreement on identified disease element clusters.
Delphi exercise
The Delphi exercise was conducted as a series of three web-based surveys using Survey 
Monkey™ software (SurveyMonkey Inc., San Mateo, CA). Physicians and non-physician 
scientists with expertise in gout were identified through their membership of G-CAN and 
invited by email to participate in the first round of the survey. Subsequent rounds were only 
made available to those who had engaged in the previous surveys. In each survey, 
respondents were presented with disease states identified by the content analysis of the 
literature, represented by the disease element clusters. Respondents were first asked if each 
proposed disease state was meaningful for disease prognosis or management. Next, 
respondents were asked to select and rank their preferred labels for each disease state from a 
list of options derived from the content analysis of the literature; labels were included if 
present in at least two of the articles analysed, with the frequency with which they occurred 
in the literature also shown. In the first round, respondents were also able to nominate their 
own preferred disease states or labels that had not already been presented; these were 
included as voting options in the second round of the Delphi if nominated by at least two 
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respondents. Respondents were given the option to comment on disease states or labels that 
they felt either strongly for or against; a thematic summary of these comments was provided 
as group feedback in subsequent rounds according to Delphi principles. Disease state label 
options were refined as the Delphi rounds progressed. Voting on whether a disease state was 
meaningful, and for its preferred label, ceased once consensus agreement was achieved, 
defined as at least 80% agreement.
Face-to-face meeting
The face-to-face meeting took place on the 20th of October 2018 in Chicago, IL. All G-CAN 
members were invited to attend irrespective of their involvement in the Delphi exercise. 
There were two main objectives for this meeting. The first objective was to address those 
disease states for which consensus agreement was not met at the conclusion of the Delphi 
exercises, either for whether they were meaningful, or for the preferred label. The second 
objective was to agree on a definition for each disease state included in the final consensus 
statement. Attendees were provided pre-reading that included a summary of the content 
analysis of the literature, results of the Delphi exercise, and draft definitions of the disease 
states as a starting point for discussion. The meeting was conducted as a facilitated 
discussion, moderated by two investigators (DB and ND). Key points raised by attendees 
were summarised, refined by group discussion, and then brought forward for voting by show 
of hands. Consensus agreement was defined as at least 80% agreement by those present at 
the time of voting.
The group was first asked to consider which of the proposed disease states should be 
included in the nomenclature based on the results of the Delphi exercise. It was agreed that 
only those disease states that had achieved consensus agreement as being meaningful 
following the three rounds of the Delphi exercise would be included. Next, disease state 
labels for which consensus agreement had not been reached during the Delphi exercise were 
discussed and voted on. Finally, the definitions for each disease state were developed and 
iteratively modified until consensus agreement was reached.
G-CAN endorsement
[The results of the project and consensus nomenclature statement have been reviewed and 
endorsed by the G-CAN Board of Directors.]
RESULTS
Content analysis of the literature
A total of 539 articles were extracted using the search criteria. Analysis of these articles 
identified 13 disease states that were categorised into preclinical states, clinical states, and 
states describing the disease course of gout (Table 2). In total, there were 63 unique labels 
identified for these 13 disease states. A detailed description of these results is shown in the 
Supplementary Material.
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Seventy-six G-CAN members responded to the first round of the survey; of these, 72 (95%) 
completed all three rounds. The respondents included 34 members from Europe (45%), 24 
from North America (32%), 13 from the Asia-Pacific region (17%), and five from Latin 
America (7%). The majority of respondents were rheumatologists (n=67, 88%); other 
physician specialists (n=4, 5%) and non-physician scientists (n=5, 7%) also participated.
Of the 13 disease states identified from the content analysis of the literature, nine were 
deemed to be meaningful by consensus agreement (Table 3). Of these nine disease states 
deemed to be meaningful, seven disease states reached consensus agreement on their 
preferred label: ‘asymptomatic hyperuricemia’, ‘asymptomatic monosodium urate crystal 
deposition’, ‘severe gout’, ‘tophaceous gout’, ‘erosive gout’, ‘first gout flare’ and ‘recurrent 
gout flares’ (Table 4). A detailed description of the Delphi exercise results regarding whether 
disease states were meaningful and preferred labels is shown in the Supplementary Material.
Face-to-face meeting
A total of 35 G-CAN members attended the face-to-face meeting, the majority of whom 
were rheumatologists (n=33, 94%). Of those attending, 32 (91%) had also participated in all 
three rounds of the Delphi exercise. The panel included 18 members from Europe (51%), 11 
from North America (31%), four from the Asia-Pacific region (11%), and two from Latin 
America (6%). The number of attendees participating in voting activities during the meeting 
varied from 28 to 35.
Agreement about which disease states are meaningful—The first item raised was 
the proposal that only disease states reaching consensus agreement as being meaningful 
during the Delphi exercise should be included within the final disease state consensus 
statement. This proposal was unanimously agreed upon (35 of 35 voting in favour), reducing 
the total number of disease states for consideration to nine; this was further reduced to eight 
when it was unanimously agreed to eliminate the disease state ‘the presence of monosodium 
urate crystals with any of the following: frequent recurrent gout flares, chronic gouty 
arthritis, subcutaneous tophi or imaging disease elements of gout’. This disease state, 
labelled ‘severe gout’ through the Delphi exercise, was thought to be a broad, non-specific 
state that would be difficult to define in clinical and research settings. It was also considered 
to be potentially misleading for gout treatment; for example, it might imply that patients not 
fulfilling this definition have ‘non-severe gout’ and that urate lowering therapy is not 
warranted in this case. For the cluster of disease elements: ‘hyperuricemia with imaging 
evidence of monosodium urate crystal deposition but without clinical disease elements of 
gout’, consensus agreement on this state being meaningful was achieved through the Delphi 
exercise. However, a number of respondents commented that this state was similar to the 
disease state, ‘asymptomatic monosodium urate crystal deposition’, and therefore may be 
redundant. After being put to vote, it was unanimously agreed (35/35 in favour) that this 
represented a unique and meaningful disease state, distinct from ‘asymptomatic 
monosodium urate crystal deposition’ which could represent a state of asymptomatic crystal 
deposition irrespective of serum urate concentration. The final eight disease states deemed 
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meaningful by consensus agreement at the conclusion of both the Delphi exercise and face-
to-face meeting are shown in Table 5.
Disease state labels—Consensus agreement was achieved on two disease state labels 
that remained unresolved after the Delphi exercise. These consensus labels were: 
‘asymptomatic hyperuricemia with monosodium urate crystal deposition’ and ‘gout’ (Table 
4). Further details on voting results are shown in Supplementary Table S2.
For the disease state referring to ‘hyperuricemia with imaging evidence of monosodium 
urate crystal deposition but without clinical disease elements of gout’, the label 
‘asymptomatic hyperuricemia with monosodium urate crystal deposition’ was very close to 
reaching consensus following the Delphi exercise with 79% agreement; after being put to 
vote, consensus agreement was reached with 33 of 35 (94%) in favor of this label.
The second disease state label that remain unresolved following the Delphi exercise 
concerned the disease state ‘the presence of monosodium urate crystals with clinical disease 
elements of gout’. The two most preferred labels for this disease state following the Delphi 
exercise were ‘gout’ (56% agreement) and ‘symptomatic gout’ (43% agreement). This 
situation raised the fundamental question of whether ‘gout’ refers to the underlying 
pathophysiological process of monosodium urate crystal deposition or the clinically evident 
sequelae of crystal deposition. Consensus agreement for the label ‘gout’ to describe the 
disease state ‘the presence of monosodium urate crystals with clinical disease elements of 
gout’ was achieved with 34 of 34 (100%, one abstention) voting in favour. Thus, consensus 
was reached that the label ‘gout’ should be reserved for clinically evident disease.
Disease state definitions—Consensus agreement was achieved for the definitions of all 
eight disease states of gout (Table 5). Relevant issues arising from group discussions on the 
composition of these definitions are outlined here. Further details on voting results are 
shown in Supplementary Table S2.
When considering the definition of the disease state of gout it was considered important to 
include reference to ‘a disease caused by monosodium urate crystal deposition’ resulting in 
clinical disease elements. Therefore ‘gout’, according to this definition, requires current or 
prior clinically evident symptoms or signs resulting from monosodium urate crystal 
deposition. The issue was also raised as to whether ‘monosodium urate crystal-proven’ 
should be used as a modifier for the label ‘gout’. Although use of this descriptor is popular 
in clinical practice, it strictly refers to method of diagnosis, which can be achieved through a 
number of modalities, including synovial fluid analysis, ultrasound or dual-energy computed 
tomography. As this does not represent a separate disease state, it was not included in the 
recommended nomenclature.
Disease state labels not specifically addressed by the nomenclature—
Throughout discussions it was acknowledged that disease states are not necessarily mutually 
exclusive and that the potential for overlap exists. It was also recognised that a consensus 
nomenclature cannot formally address all combinations of disease elements of gout. This led 
to the suggestion of a hierarchical approach to address those disease states that are not 
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formally included in the agreed nomenclature. Specifically, the following recommendation 
was proposed: ‘Where there is more than one disease state present, these can be combined 
(for example, ‘tophaceous and erosive gout’). Where there are additional elements present, 
not recognized as disease states, these will be labelled as the recognized disease state with or 
without additional disease elements (for example, ‘tophaceous gout with chronic gouty 
arthritis’)’. This proposal was unanimously agreed on with 27 of 27 voting in favour (100%, 
one abstention).
DISCUSSION
In this project, we have achieved consensus agreement on the labels and definitions for 
disease states of gout. This project builds on the G-CAN-endorsed nomenclature for the 
disease elements of gout,7 which provided a foundation for both the extraction of disease 
element clusters in the content analysis of the literature, and for the formulation of disease 
state terminology. The G-CAN endorsed labels for disease elements and for disease states 
should be used concurrently where appropriate. These technical language labels and 
definitions for disease states [which have been endorsed by G-CAN] have been developed 
for use by health care professionals and non-physician scientists in clinical and research 
settings.
Our content analysis of the literature demonstrated that the existing terminology of the 
disease states of gout is deficient in a number of key areas. Disease states were, in general, 
infrequently mentioned, poorly defined or inconsistently labelled in the large body of 
contemporary gout-related literature that was analysed. With the exception of ‘asymptomatic 
hyperuricemia’, little mention was made of pre-clinical disease states defined by the 
presence of monosodium urate crystal deposition on imaging and the absence of clinical 
disease elements of gout. Given the latest advances and increasing availability of advanced 
imaging such as ultrasound and dual-energy computed tomography (DECT) in the detection 
of monosodium urate crystal deposition, there is a need to consistently label and define these 
pre-clinical states. This project has provided consensus labels and definitions for two further 
pre-clinical disease states: ‘asymptomatic monosodium urate crystal deposition’ and 
‘asymptomatic hyperuricemia with monosodium urate crystal deposition’.
One of the key outcomes of this project was defining the label ‘gout’. There was much 
discussion about what constitutes ‘gout’, whether it is the presence of monosodium urate 
crystal deposition, or more specifically, the clinical manifestations resulting from this crystal 
deposition. In this consensus statement, we recommend the label ‘gout’ be used only when 
there are current or prior clinical symptoms or signs of monosodium urate crystal deposition. 
The prognostic significance of asymptomatic monosodium urate crystal deposition is 
currently uncertain and we recommend that the label ‘gout’ is not used in the absence of 
current or prior clinical symptoms or signs caused by monosodium urate crystal deposition. 
Another key outcome was the rejection of non-specific labels of the clinical features of gout, 
such as ‘severe gout’, which are, despite their ambiguity, present in a number of 
international gout management guidelines.8–11 Where cluster of elements cannot be 
described using a single label, guidance has been provided for the use of consistent 
nomenclature.
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In summary, this consensus statement presents recommended labels and definitions for 
disease states of gout. The Gout, Hyperuricemia and Crystal-Associated Disease Network 
(G-CAN) recommends the use of these labels when communicating in the scientific 
literature and in professional practice.
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• The language used to describe gout is characterised by a lack of consistent 
terminology and definitions.
• Consensus agreement has been reached about the labels and definitions of 
disease states of gout.
• The agreed labels are: ‘asymptomatic hyperuricemia’, ‘asymptomatic 
monosodium urate crystal deposition’, ‘asymptomatic hyperuricemia with 
monosodium urate crystal deposition’, ‘gout’, ‘tophaceous gout’, ‘erosive 
gout’, ‘first gout flare’ and ‘recurrent gout flares’.
• The label ‘gout’ should be restricted to current or prior clinically evident 
disease caused by monosodium urate crystal deposition.
• The Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN) 
recommends the use of these labels when communicating in the scientific 
literature and in professional practice.
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Outline of the project to develop the Gout, Hyperuricemia and Crystal-Associated Disease 
Network (G-CAN) consensus statement regarding the labels and definitions of disease states 
of gout.
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Table 1.
G-CAN endorsed labels and definitions of the disease elements of gout7
Consensus label Consensus definition
Chemical elements
1. Monosodium urate crystals The pathogenic crystals in gout (chemical formula: C5H4N4NaO3).
2. Urate
The circulating form of the final enzymatic product generated by xanthine oxidase 
in purine metabolism in humans (chemical formula: C5H3N4O3−).
3. Hyperuricemia† Elevated blood urate concentration over the saturation threshold.
Clinical elements
4. Gout flare A clinically evident episode of acute inflammation induced by monosodium urate crystals.
5. Intercritical gout The asymptomatic period after or between gout flares, despite the persistence of monosodium urate crystals.
6. Chronic gouty arthritis Persistent joint inflammation induced by monosodium urate crystals.
6a. G-CAN recommendation The label ‘chronic gout’ should be avoided.
7. Tophus An ordered structure of monosodium urate crystals and the associated host tissue response.
8. Subcutaneous tophus A tophus that is detectable by physical examination.
9. Podagra A gout flare at the 1st metatarsophalangeal joint.
Imaging elements
10. Imaging evidence of 
monosodium urate crystal 
deposition
Findings that are highly suggestive of monosodium urate crystals on an imaging 
test.
11. Gouty bone erosion Evidence of a cortical break in bone suggestive of gout (overhanging edge with sclerotic margin).
†
In British English, hyperuricaemia.
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Table 5.
G-CAN endorsed labels and definitions for the disease states of gout.
Consensus label Consensus definition
Preclinical states
 1. Asymptomatic hyperuricemia† Hyperuricemia† in the absence of gout.
 2. Asymptomatic monosodium 
urate crystal deposition
Evidence of monosodium urate crystal deposition in the absence of gout. 
Monosodium urate crystal deposition may be demonstrated by imaging or 
microscopic analysis.
 3. Asymptomatic hyperuricemia† 
with monosodium urate crystal 
deposition
Hyperuricemia† with evidence of monosodium urate crystal deposition in the 
absence of gout. Monosodium urate crystal deposition may be demonstrated 
by imaging or microscopic analysis.
Clinical states
 4. Gout A disease caused by monosodium urate crystal deposition with any of the 
following clinical presentations (current or prior): gout flare, chronic gouty 
arthritis or subcutaneous tophus.
 5. Tophaceous gout Gout with at least one subcutaneous tophus.
 6. Erosive gout Gout with at least one gouty bone erosion.
Disease course 
states
 7. First gout flare The first episode of gout flare.
 8. Recurrent gout flares More than one gout flare.
Additional recommendation on disease states not 
addressed by the nomenclature
Where there is more than one disease state present, these can be combined 
(for example: tophaceous and erosive gout). Where there are additional 
elements present, not recognized as disease states, these will be labelled as the 
recognized disease state with or without additional disease elements (for 
example: tophaceous gout with chronic gouty arthritis).
†
In British English, hyperuricaemia.
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